Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

We report here the results of a phase 3 study to assess the efficacy, safety, and tolerability of GC5107, a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials.gov: NCT02783482). Over a 12-month study p...

Full description

Bibliographic Details
Main Authors: Elena E. Perez, Jacques Hébert, Anne K. Ellis, Oral Alpan, William R. Lumry, Ralph Shapiro, Daniel Suez, J. Fernando Mandujano, Richard L. Wasserman
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
primary immunodeficiency disease
inborn errors of immunity
immune globulin intravenous
intravenous immune globulin
immunoglobulin replacement therapy
IVIG
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.707463/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.707463/full

Similar Items